Implant device with a retinoid for improved biocompatibility

• US 6,306,426 B1
• Filed: 06/05/2000
• Issued: 10/23/2001
• Est. Priority Date: 08/11/1997
• Status: Expired due to Term

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan Sales LLC (Abbvie Incorporated)
• Inventors: Hughes, Patrick M., Olejnik, Orest, Kent, John S.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Seidleck, Brian K.
• Application Number:
  US09/587,485
• Time in Patent Office: 505 Days
• Field of Search: 424/422, 424/423, 424/424, 424/426, 424/427, 424/428, 514/725, 514/953, 514/954, 514/955, 604/890.1, 604/892.1
• US Class Current: 424/426
• CPC Class Codes: A61K 31/07 Retinol compounds, e.g. vitamin A retinoic acids A61K31/203
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/442 Colorants, dyes
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.

Claims

1. An implantable device for providing systemic or local release of a therapeutic agent in tissue, the device comprising:

a therapeutic agent;

a carrier sized for insertion into tissue in which systemic release of the therapeutic agent is desired, said carrier including means for providing controlled release of the therapeutic agent wherein said means comprises a biodegradable polymer; and

a retinoid, separate from the therapeutic agent and homogeneously distributed throughout the device for improving biocompatibility of said device in said tissue.

2. The device according to claim 1 wherein said retinoid comprises a retinoid receptor agonist.

3. The device according to claim 2 wherein said therapeutic agent, carrier and retinoid are homogeneous.

4. The device according to claim 1 wherein said biodegradable polymer comprises a poly(lactic acid).

5. The device according to claim 1 wherein said biodegradable polymer comprises poly(lactide-co-glycolide).

6. The device according to claim 2 wherein said retinoid receptor agonist comprises a naturally occurring retinoid.

7. The device according to claim 2 wherein said retinoid receptor agonist is selected from a group consisting of Vitamin A (retinal), Vitamin A aldehyde (retinal), Vitamin A acid (retinoic acid) and their synthetic and natural congeners.

8. The device according to claim 2 wherein the retinoid receptor agonist comprises ethy-6-[2-(4,4-dimethylthiochroman-6yl) ethynyl]nicotinate.

9. The device according to claim 2 wherein the retinoid receptor agonist comprises 6-[2-(4,4-dimethylchroman-6-yl)ethynyl]nicotinic acid.

10. The device according to claim 2 wherein the retinoid receptor agonist comprises p-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2naphthyl)propenyl]-benzoic acid.